Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$188.95
+0.4%
$177.04
$140.68
$189.92
$453.15B0.48.70 million shs8.69 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$9.22
+1.5%
$8.22
$5.01
$13.61
$1.47B2.744.49 million shs4.21 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.27
-0.6%
$24.76
$20.92
$30.43
$150.27B0.5562.68 million shs47.61 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.38%+1.91%+6.04%+21.07%+18.42%
Novavax, Inc. stock logo
NVAX
Novavax
+1.54%+6.34%+16.71%+30.97%-29.19%
Pfizer Inc. stock logo
PFE
Pfizer
-0.68%+3.18%+5.69%+2.78%-10.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$188.95
+0.4%
$177.04
$140.68
$189.92
$453.15B0.48.70 million shs8.69 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$9.22
+1.5%
$8.22
$5.01
$13.61
$1.47B2.744.49 million shs4.21 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.27
-0.6%
$24.76
$20.92
$30.43
$150.27B0.5562.68 million shs47.61 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.38%+1.91%+6.04%+21.07%+18.42%
Novavax, Inc. stock logo
NVAX
Novavax
+1.54%+6.34%+16.71%+30.97%-29.19%
Pfizer Inc. stock logo
PFE
Pfizer
-0.68%+3.18%+5.69%+2.78%-10.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.68
Moderate Buy$189.880.49% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.00
Hold$14.2954.94% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.37
Hold$28.418.15% Upside

Current Analyst Ratings Breakdown

Latest PFE, NVAX, and JNJ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/7/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$200.00 ➝ $213.00
10/6/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Perform$172.00 ➝ $193.00
10/3/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$198.00
10/3/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetEqual WeightOverweight$170.00 ➝ $212.00
10/3/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeEqual WeightOverweight$170.00 ➝ $212.00
10/3/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$175.00 ➝ $198.00
10/3/2025
Pfizer Inc. stock logo
PFE
Pfizer
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$28.00 ➝ $30.00
10/1/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$28.00
9/30/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price Target$188.00 ➝ $210.00
9/27/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
9/27/2025
Novavax, Inc. stock logo
NVAX
Novavax
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$88.82B5.12$13.18 per share14.34$29.69 per share6.36
Novavax, Inc. stock logo
NVAX
Novavax
$682.16M2.20N/AN/A($3.89) per share-2.37
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.35$4.33 per share6.06$15.62 per share1.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$9.3520.2117.072.4025.00%32.49%13.00%10/14/2025 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$187.50M$2.284.04115.250.1239.20%-142.33%28.65%11/11/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.8813.978.670.8616.84%21.42%9.12%11/4/2025 (Estimated)

Latest PFE, NVAX, and JNJ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2025Q3 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.79N/AN/AN/A$16.94 billionN/A
10/14/2025Q3 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.78N/AN/AN/A$23.73 billionN/A
8/6/2025Q2 2025
Novavax, Inc. stock logo
NVAX
Novavax
-$0.07$0.62+$0.69$0.62$149.19 million$239.24 million
8/5/2025Q2 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.58$0.78+$0.20$0.51$13.43 billion$14.65 billion
7/16/2025Q2 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.202.75%N/A55.61%64 Years
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.55%N/A91.49%16 Years

Latest PFE, NVAX, and JNJ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.303.35%8/26/20258/26/20259/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.50
1.01
0.76
Novavax, Inc. stock logo
NVAX
Novavax
5.93
2.36
2.34
Pfizer Inc. stock logo
PFE
Pfizer
0.65
1.16
0.85

Institutional Ownership

CompanyInstitutional Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,1002.41 billion2.40 billionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990162.42 million160.80 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable

Recent News About These Companies

Brokerages Set Pfizer Inc. (NYSE:PFE) Target Price at $28.41
Life sciences sentiment rises as Pfizer deal eases tariff concerns
Down 50%, Should You Buy the Dip on Pfizer?
Down 50%, Should You Buy the Dip on Pfizer?
TrumpRx Brings Pfizer Into the Green-Is It a Buy?
Smartphone with Pfizer Logo against blue tablets and capsules Background — Stock Editorial Photography
TrumpRx Brings Pfizer Into the Green—Is It a Buy?
...
Pfizer Inc. $PFE Stake Cut by Simplicity Wealth LLC
Pfizer (NYSE:PFE) Shares Down 3.4% - Time to Sell?
Eli Lilly oral GLP-1 medication
Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal (PFE)
...
A grocery cart with two bottles of pharmaceuticals is heading down a steep down ramp
Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
...

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$188.95 +0.79 (+0.42%)
Closing price 10/7/2025 03:59 PM Eastern
Extended Trading
$188.40 -0.55 (-0.29%)
As of 05:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Novavax stock logo

Novavax NASDAQ:NVAX

$9.22 +0.14 (+1.54%)
Closing price 10/7/2025 04:00 PM Eastern
Extended Trading
$9.26 +0.04 (+0.49%)
As of 05:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Pfizer stock logo

Pfizer NYSE:PFE

$26.27 -0.16 (-0.61%)
Closing price 10/7/2025 03:59 PM Eastern
Extended Trading
$26.30 +0.04 (+0.13%)
As of 05:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.